NUZ — Neurizon Therapeutics Cashflow Statement
0.000.00%
- AU$62.62m
- AU$53.22m
Annual cashflow statement for Neurizon Therapeutics, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | 2026 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Changes in Working Capital | 1.13 | 1.08 | 0.867 | 1.9 | 6.16 |
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -1.33 | -1.56 | -5.17 | -14.3 | -15.1 |
| Capital Expenditures | -0.043 | -0.035 | 0 | -0.002 | -0.008 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0 | -0 | -1.17 | -0.02 | 0 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Change in Net Intangibles | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -0.043 | -0.035 | -1.17 | -0.022 | -0.008 |
| Financing Cash Flow Items | — | — | 0.035 | -0.035 | 0 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 0.771 | 1.89 | 13.3 | 8.76 | 23.5 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -0.605 | 0.29 | 7.01 | -5.55 | 8.53 |